Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Sales of Investments
Cash received from selling or redeeming investments.
Sagimet Biosciences Inc.NASDAQ: SGMT
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments dips below year-ago levels
Q1 FY2026 sales of investments of $16.97M fell 10.6% year over year, behind the +75.3% change in trailing-twelve-month sales of investments. Sequentially, it fell 46.0% from the prior quarter. Over 3 fiscal years it compounded at +127.7% a year.
Context
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -10.6% toward the trailing-twelve-month pace of +75.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 111.42M USD
- Year-over-year change
- +140.1%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.42M | +140.1% |
| FY2024 | 2024-12-31 | 46.4M | +44.1% |
| FY2023 | 2023-12-31 | 32.2M | +241.2% |
| FY2022 | 2022-12-31 | 9.44M | — |
| FY2021 | 2021-12-31 | 0 | — |
Sales of Investments vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's LTM Mar 2026 sales of investments of $109.4M is the 6th largest of the 11 companies compared; the peer median is $89.59M.
- Its year-over-year change of +75.3% is the highest of 8, against a peer median of -23.0%.
- Over three fiscal years its annual growth of +127.7% compares with a peer median of +50.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $366.77M | -26.9% | +72.4% | — | |
| LTM Mar 2026 | $212.37M | -43.4% | +50.4% | 3701.1% | |
| LTM Mar 2026 | $212M | -16.7% | +13.5% | 751.1% | |
| LTM Mar 2026 | $194.74M | -49.2% | +73.7% | 533.6% | |
| LTM Mar 2026 | $147.6M | +8.4% | -0.1% | 207.6% | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $109.4M | +75.3% | +127.7% | — |
| LTM Mar 2026 | $31.58M | -23.0% | — | — | |
| LTM Mar 2026 | $9M | -14.3% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding SGMT) | $89.59M | -23.0% | +50.4% | 370.6% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 1.9M | 1.88M | 4.99M | 5.29M | 6.45M |
| Change in Working Capital | (55K) | 4.21M | (978K) | (1.05M) | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 120K | (907K) | 929K |
| Other Working Capital | (55K) | 4.21M | (1.1M) | (141K) | (1.98M) |
| Other Non-Cash Items | 883K | (215K) | 98K | (1.11M) | (8K) |
| Operating Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (41.45M) | (19.62M) | (108.09M) | (106.86M) |
| Sales of Investments | 0 | 9.44M | 32.2M | 46.4M | 111.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (32.01M) | 12.58M | (61.68M) | 4.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 12K | 89.68M | 105.75M | 275K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.07M) | (85K) | (3.51M) | (931K) | 0 |
| Financing Cash Flow | 9.74M | (73K) | 86.17M | 104.82M | 275K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.97M) | (56.57M) | 74.98M | 701K | (40.82M) |
| Free Cash Flow | (21.71M) | (24.49M) | (23.77M) | (42.44M) | (45.65M) |
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.